Use of MMP-8 and MMP-9 to assess disease severity in children with viral lower respiratory tract infections

Journal of Medical Virology

Volumn 84, Issue 9, 2012, Pages 1471-1480

  Brand, Kim H ^a   Ahout, Inge M L ^a   De Groot, Ronald ^a   Warris, Adilia ^a   Ferwerda, Gerben ^a   Hermans, Peter W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Disease severity; Matrix metalloproteinases; Viral respiratory infections

Indexed keywords

GELATINASE B; MESSENGER RNA; NEUTROPHIL COLLAGENASE;

ARTICLE; CHILD; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; NASOPHARYNGEAL ASPIRATION; NEUTROPHIL; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRAL LOWER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

FEMALE; GENE EXPRESSION; GRANULOCYTES; HELA CELLS; HUMANS; INFANT; LEUKOCYTES, MONONUCLEAR; MALE; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; NASAL MUCOSA; NEUTROPHILS; PHARYNX; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

RICE STRIPE VIRUS;

EID: 84864135737     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23301     Document Type: Article

References (55)

1. Abe M, Kawamoto K, Okamoto H, Horiuchi N. 2001. Induction of collagenase-2 (matrix metalloproteinase-8) gene expression by interleukin-1beta in human gingival fibroblasts. J Periodontal Res 36: 153-159.
2. Albaiceta GM, Gutierrez-Fernandez A, Garcia-Prieto E, Puente XS, Parra D, Astudillo A, Campestre C, Cabrera S, Gonzalez-Lopez A, Fueyo A, Taboada F, Lopez-Otin C. 2010. Absence or inhibition of matrix metalloproteinase-8 decreases ventilator-induced lung injury. Am J Respir Cell Mol Biol 43: 555-563.
3. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr., Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
4. Allantaz F, Chaussabel D, Stichweh D, Bennett L, Allman W, Mejias A, Ardura M, Chung W, Smith E, Wise C, Palucka K, Ramilo O, Punaro M, Banchereau J, Pascual V. 2007. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 204: 2131-2144.
5. Belleguic C, Corbel M, Germain N, Lena H, Boichot E, Delaval PH, Lagente V. 2002. Increased release of matrix metalloproteinase-9 in the plasma of acute severe asthmatic patients. Clin Exp Allergy 32: 217-223.
6. Berger TM, Aebi C, Duppenthaler A, Stocker M. 2009. Prospective population-based study of RSV-related intermediate care and intensive care unit admissions in Switzerland over a 4-year period (2001-2005). Infection 37: 109-116.
7. Black CP. 2003. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 48: 209-231.
8. Boyce TG, Mellen BG, Mitchel EF, Jr., Wright PF, Griffin MR. 2000. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 137: 865-870.
9. Brand HK, Hermans PW, de Groot R. 2010. Host biomarkers and paediatric infectious diseases: From molecular profiles to clinical application. Adv Exp Med Biol 659: 19-31.
10. Chaussabel D, Quinn C, Shen J, Patel P, Glaser C, Baldwin N, Stichweh D, Blankenship D, Li L, Munagala I, Bennett L, Allantaz F, Mejias A, Ardura M, Kaizer E, Monnet L, Allman W, Randall H, Johnson D, Lanier A, Punaro M, Wittkowski KM, White P, Fay J, Klintmalm G, Ramilo O, Palucka AK, Banchereau J, Pascual V. 2008. A modular analysis framework for blood genomics studies: Application to systemic lupus erythematosus. Immunity 29: 150-164.
11. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L, Meeking P, Mann A, Moane E, Oxford J, Pareek R, Moore R, Walsh E, Studholme R, Dorsett P, Alvarez R, Lambkin-Williams R. 2010. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 182: 1305-1314.
12. Dezzutti CS, Hendrix CW, Marrazzo JM, Pan Z, Wang L, Louissaint N, Kalyoussef S, Torres NM, Hladik F, Parikh U, Mellors J, Hillier SL, Herold BC. 2011. Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS ONE 6: e23136.
13. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, DeVincenzo JP. 2011. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis 204: 996-1002.
14. Elliott MB, Welliver RC, Sr., Laughlin TS, Pryharski KS, LaPierre NA, Chen T, Souza V, Terio NB, Hancock GE. 2007. Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in the respiratory tracts of human infants following paramyxovirus infection. J Med Virol 79: 447-456.
15. Faurschou M, Borregaard N. 2003. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 5: 1317-1327.
16. Fligiel SE, Standiford T, Fligiel HM, Tashkin D, Strieter RM, Warner RL, Johnson KJ, Varani J. 2006. Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. Hum Pathol 37: 422-430.
17. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. 1997. Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 74: 111-122.
18. Greenlee KJ, Werb Z, Kheradmand F. 2007. Matrix metalloproteinases in lung: Multiple, multifarious, and multifaceted. Physiol Rev 87: 69-98.
19. Hartog CM, Wermelt JA, Sommerfeld CO, Eichler W, Dalhoff K, Braun J. 2003. Pulmonary matrix metalloproteinase excess in hospital-acquired pneumonia. Am J Respir Crit Care Med 167: 593-598.
20. Henrickson KJ, Hoover S, Kehl KS, Hua W. 2004. National disease burden of respiratory viruses detected in children by polymerase chain reaction. Pediatr Infect Dis J 23: S11-S18.
21. Hirschfeld M, Ma Y, Weis JH, Vogel SN, Weis JJ. 2000. Cutting edge: Repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol 165: 618-622.
22. Hoggatt J. 2011. Personalized medicine-Trends in molecular diagnostics: Exponential growth expected in the next ten years. Mol Diagn Ther 15: 53-55.
23. Houben ML, Coenjaerts FE, Rossen JW, Belderbos ME, Hofland RW, Kimpen JL, Bont L. 2010. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. J Med Virol 82: 1266-1271.
24. Hrabec E, Strek M, Zieba M, Kwiatkowska S, Hrabec Z. 2002. Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. Int J Tuberc Lung Dis 6: 713-719.
25. Iwane MK, Edwards KM, Szilagyi PG, Walker FJ, Griffin MR, Weinberg GA, Coulen C, Poehling KA, Shone LP, Balter S, Hall CB, Erdman DD, Wooten K, Schwartz B. 2004. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 113: 1758-1764.
26. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. 2007. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20: 108-119.
27. Knauper V, Osthues A, DeClerck YA, Langley KE, Blaser J, Tschesche H. 1993. Fragmentation of human polymorphonuclear-leucocyte collagenase. Biochem J 291: 847-854.
28. Kong MY, Gaggar A, Li Y, Winkler M, Blalock JE, Clancy JP. 2009. Matrix metalloproteinase activity in pediatric acute lung injury. Int J Med Sci 6: 9-17.
29. Li W, Shen HH. 2007. Effect of respiratory syncytial virus on the activity of matrix metalloproteinase in mice. Chin Med J (Engl) 120: 5-11.
30. Lukens MV, van de Pol AC, Coenjaerts FE, Jansen NJ, Kamp VM, Kimpen JL, Rossen JW, Ulfman LH, Tacke CE, Viveen MC, Koenderman L, Wolfs TF, van Bleek GM. 2010. A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants. J Virol 84: 2374-2383.
31. Mansbach JM, Clark S, Christopher NC, LoVecchio F, Kunz S, Acholonu U, Camargo CA, Jr. 2008. Prospective multicenter study of bronchiolitis: Predicting safe discharges from the emergency department. Pediatrics 121: 680-688.
32. Mattos W, Lim S, Russell R, Jatakanon A, Chung KF, Barnes PJ. 2002. Matrix metalloproteinase-9 expression in asthma: Effect of asthma severity, allergen challenge, and inhaled corticosteroids. Chest 122: 1543-1552.
33. Mautino G, Capony F, Bousquet J, Vignola AM. 1999. Balance in asthma between matrix metalloproteinases and their inhibitors. J Allergy Clin Immunol 104: 530-533.
34. Munywoki PK, Hamid F, Mutunga M, Welch S, Cane P, Nokes DJ. 2011. Improved detection of respiratory viruses in pediatric outpatients with acute respiratory illness by real-time PCR using nasopharyngeal flocked swabs. J Clin Microbiol 49: 3365-3367.
35. Nakamura T, Ebihara I, Shimada N, Shoji H, Koide H. 1998. Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: Effect of fiber-immobilized polymyxin B treatment. Am J Med Sci 316: 355-360.
36. Norwood A, Mansbach JM, Clark S, Waseem M, Camargo CA, Jr. 2010. Prospective multicenter study of bronchiolitis: Predictors of an unscheduled visit after discharge from the emergency department. Acad Emerg Med 17: 376-382.
37. Obase Y, Rytila P, Metso T, Pelkonen AS, Tervahartiala T, Turpeinen M, Makela M, Saarialho-Kere U, Selroos O, Sorsa T, Haahtela T. 2010. Effects of inhaled corticosteroids on metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in the airways of asthmatic children. Int Arch Allergy Immunol 151: 247-254.
38. Openshaw PJ. 2005. Antiviral immune responses and lung inflammation after respiratory syncytial virus infection. Proc Am Thorac Soc 2: 121-125.
39. Prikk K, Maisi P, Pirila E, Reintam MA, Salo T, Sorsa T, Sepper R. 2002. Airway obstruction correlates with collagenase-2 (MMP-8) expression and activation in bronchial asthma. Lab Invest 82: 1535-1545.
40. Purcell K, Fergie J. 2004. Driscoll Children's Hospital respiratory syncytial virus database: Risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatr Infect Dis J 23: 418-423.
41. Quinn B. 2010. Payers and the assessment of clinical utility for companion diagnostics. Clin Pharmacol Ther 88: 751-754.
42. Ramilo O, Allman W, Chung W, Mejias A, Ardura M, Glaser C, Wittkowski KM, Piqueras B, Banchereau J, Palucka AK, Chaussabel D. 2007. Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 109: 2066-2077.
43. Ricou B, Nicod L, Lacraz S, Welgus HG, Suter PM, Dayer JM. 1996. Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med 154: 346-352.
44. Roback MG, Baskin MN. 1997. Failure of oxygen saturation and clinical assessment to predict which patients with bronchiolitis discharged from the emergency department will return requiring admission. Pediatr Emerg Care 13: 9-11.
45. Schaaf B, Liebau C, Kurowski V, Droemann D, Dalhoff K. 2008. Hospital acquired pneumonia with high-risk bacteria is associated with increased pulmonary matrix metalloproteinase activity. BMC Pulm Med 8.
46. Schuurhof A, Bont L, Hodemaekers HM, de Klerk F A, de Groot H, Hofland RW, van de Pol AC, Kimpen JL, Janssen R. 2012. Proteins involved in extracellular matrix dynamics are associated with RSV disease severity. Eur Respir J.
47. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. 1999. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282: 1440-1446.
48. Templeton KE, Scheltinga SA, Beersma MF, Kroes AC, Claas EC. 2004. Rapid and sensitive method using multiplex real-time PCR for diagnosis of infections by influenza A and influenza B viruses, respiratory syncytial virus, and parainfluenza viruses 1, 2 3, and 4. J Clin Microbiol 42: 1564-1569.
49. Thrailkill KM, Moreau CS, Cockrell G, Simpson P, Goel R, North P, Fowlkes JL, Bunn RC. 2005. Physiological matrix metalloproteinase concentrations in serum during childhood and adolescence, using Luminex Multiplex technology. Clin Chem Lab Med 43: 1392-1399.
50. Vignola AM, Riccobono L, Mirabella A, Profita M, Chanez P, Bellia V, Mautino G, D'accardi P, Bousquet J, Bonsignore G. 1998. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 158: 1945-1950.
51. Wang EE, Law BJ, Stephens D. 1995. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 126: 212-219.
52. Welliver TP, Reed JL, Welliver RC, Sr. 2008. Respiratory syncytial virus and influenza virus infections: Observations from tissues of fatal infant cases. Pediatr Infect Dis J 27: S92-S96.
53. Yang SF, Chu SC, Chiang IC, Kuo WF, Chiou HL, Chou FP, Kuo WH, Hsieh YS. 2005. Excessive matrix metalloproteinase-9 in the plasma of community-acquired pneumonia. Clin Chim Acta 352: 209-215.
54. Yeo SJ, Yun YJ, Lyu MA, Woo SY, Woo ER, Kim SJ, Lee HJ, Park HK, Kook YH. 2002. Respiratory syncytial virus infection induces matrix metalloproteinase-9 expression in epithelial cells. Arch Virol 147: 229-242.
55. Zaas AK, Chen M, Varkey J, Veldman T, Hero AO III, Lucas J, Huang Y, Turner R, Gilbert A, Lambkin-Williams R, Oien NC, Nicholson B, Kingsmore S, Carin L, Woods CW, Ginsburg GS. 2009. Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe 6: 207-217.